The final report in a 3-part research series on workers’ compensation medications that represent a relatively small share of the dispensed prescriptions within their therapeutic drug group, but due to their high average reimbursements, account for a disproportionate share of the total drug spend within their group. Part 3 of the series focuses on Musculoskeletal and Ulcer Drugs.